SecBot SecBot
8-K ·Filed Jul 14, 2026

SPRO

Spero Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed4mo ago SEC0001193125-26-302473
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The strategic pivot to immunology with non-dilutive capital is a strong catalyst. Monitor Phase 2 initiation in IgG4-RD in Q2 2027 and any data from Innovent's SjD Phase 2 in China. The Utebzi royalty stream provides a downside floor, but clinical development risk remains high. Watch for potential partnership expansion or additional financing needs.

DirectionBullish
Confidencehigh
Horizonmonths

SP001

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2-ready (Phase 1 completed in healthy volunteers and Sjögren's disease)
Time to market
5+ years (Phase 2 starting Q2 2027; IgG4-RD is an orphan indication but still requires Phase 2 and Phase 3)
Next catalyst
None dated

What to watchSP001 is a new pipeline asset for Spero, announced alongside a $105M non-dilutive royalty financing from Utebzi sales. Watch for the Phase 2 initiation in IgG4-RD (Q2 2027) as the next catalyst. The stock may re-rate on execution towards Phase 2 start, but the $1.1B milestone burden relative to Spero's ~$126M market cap is a significant overhang. Monitor Innovent's Phase 2 SjD data in China (early 2027) as a read-through for the mechanism.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.70
T+0 close · Jul 14, 2026 · via day close
Latest settled
−31.18%
T+60 · $1.17
Vs SPY
−34.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 14 $1.70entry
  2. T+1 · 4mo ago 0.00%α −0.40% · $1.70
  3. T+5 · 4mo ago −15.29%α −14.00% · $1.44
  4. T+20 · 3mo ago −27.65%α −30.14% · $1.23
  5. T+60 · 6w ago −31.18%α −34.55% · $1.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spero Therapeutics in-licensed SP001 (IBI355), a Phase 2-ready anti-CD40L antibody, from Innovent Biologics for $35M upfront and up to ~$1.1B in milestones + tiered royalties, marking a strategic pivot to immunology. Concurrently, it secured $105M non-recourse, non-dilutive royalty financing backed by future Utebzi (tebipenem pivoxil) milestones and royalties from GSK, extending cash runway into 2H 2029. The company plans to initiate a Phase 2 trial in IgG4-RD in Q2 2027.

Key Financial Metrics

Deal Value
$1.1B
Deal Type
license

Key Facts

  • Exclusive license for SP001 (IBI355) from Innovent, covering global rights ex-Greater China
  • $35M upfront payment to Innovent; up to $1.05B in development, regulatory, and commercial milestones
  • $105M non-recourse financing from HCRx (KKR), backed by a portion of GSK's Utebzi milestone/royalty payments
  • Cash runway extended into second half of 2029
  • Phase 2 trial in IgG4-RD expected to start Q2 2027; Innovent plans Phase 2 in Sjögren's disease in China by early 2027
  • SP001 is a third-generation Fc-silent anti-CD40L mAb with Phase 1b safety/efficacy data in Sjögren's disease

Financial Impact

$35M upfront payment to Innovent + up to $1.1B in contingent milestones; $105M non-dilutive financing provides immediate capital; no dilution to common equity

cash runwaydebtdilution

Risk Factors

  • Clinical development risk for SP001 in IgG4-RD and other indications
  • Milestone payments create a significant future financial obligation to Innovent
  • Competition from other CD40L-targeting agents and B-cell therapies
  • Dependence on GSK's commercialization of Utebzi for royalty stream to service the HCRx financing
  • No approved products in immunology pipeline; execution risk in new therapeutic area

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-302473
Document: d320658dex993.htm0001193125-26-302473
Document: d320658dex991.htm0001193125-26-302473
Document: d320658dex992.htm0001193125-26-302473
Document: 0001193125-26-302473-index-headers.html0001193125-26-302473
Document: 0001193125-26-302473-index.html0001193125-26-302473
Document: 0001193125-26-302473.txt0001193125-26-302473

Track record

17 reports on SPRO

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
  2. Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  3. Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
  5. Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
  6. Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  7. Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  8. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
  9. Jul 14, 202617w ago 8-K Bullish 8/10 Viewing Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
  10. Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (9h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026